For short-term use, it has approved phentermine, diethylpropion and phendimetrazine. A new crop of weight-loss drugs is moving toward FDA consideration in ...
The claim is that the company was aware of the risks of psychiatric side effects before the drug was licensed. Rimonabant is not the only obesity drug ...
They have both been around since the 1950's and have not been proven to show any sort of lasting side effects. However, there are some short-term side ...
Most recently, rimonabant (Acomplia; Sanofi-Aventis) faced European withdrawal following European Commission concerns over psychiatric side effects. ...
